COVID-19
Conditions
Interventions
Drug group:Basic treatment+Lianhua Qingke tablet, 4 tablets/time, 3 times/day
Control grou:Basic treatment
Sponsors
Hebei Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. It meets the diagnostic criteria for novel coronavirus pneumonia; 2. Age >= 18 years; 3. The first nucleic acid positive time is within 72h; 4. Cough symptoms at admission; 5. The patient or family member knows the research content and voluntarily signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac insufficiency, liver and kidney failure; 2. The expected survival time of patients is less than 14 days due to basic diseases, such as poor control of malignant tumors, cardiac arrest in the past 30 days, etc; 3. Patients with serious mental illness; 4. Pregnant or preparing for pregnancy, or unable to take effective contraceptive measures; 5. Allergies to the active ingredients of the test drug or its excipients; 6. Participated in clinical intervention test in recent 3 months; 7. Subjects who the researcher thinks are not suitable to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The disappearance rate and median time of clinical symptoms (cough, expectoration, fatigue, sore throat, dry throat, fever, nasal congestion, runny nose, etc.); | — |
Secondary
| Measure | Time frame |
|---|---|
| Disappearance rate of cough and other single clinical symptoms;Changes of alveolar injury markers, inflammatory factors, antibody content and antibody typing in blood components of the two groups;Proportion of the two groups converted to heavy/dangerous heavy;Mortality rate of two groups of patients with novel coronavirus pneumonia during treatment;Nucleic acid negative rate and length of hospitalization in the two groups;Changes of CT/X-ray imaging examination of chest in both groups; | — |
Countries
China
Contacts
Public ContactShucai Wu
Hebei Chest Hospital
Outcome results
None listed